Clinical Trial Update: Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma [Phase 2]

View source ↗

Summary

Phase II clinical trial update for sacituzumab govitecan in SMARCB1-deficient renal medullary carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Medullary Carcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase II, Sacituzumab | Phase 2 | Status: NOT_YET_RECRUITING